** Shares of medical technology company Sanara MedTech
rise about 2.7% to $34.6
** H.C. Wainwright initiates coverage of SMTI with "buy" rating
** Brokerage says SMTI's successful market penetration and geographic expansion could continue to drive topline growth in the coming quarters
** Company's products and services improve clinical outcomes in the surgical and chronic wound care markets, which also reduce healthcare expenditure - brokerage
** "Commercialized surgical wound care products have been driving revenue growth since 2019" - H.C. Wainwright
** Brokerage sets PT at $50, about 48.4% upside on stock's last close
** Including session's moves, stock down ~16.1% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.